FGL1 and LAG-3 are closely related to the prognosis and clinicopathological features of various types of cancer [37], and clinical studies have shown that dual FGL1/LAG-3 and PD-1/PD-L1 blockade therapy has promising survival benefits and long-duration response rates [38]. Here, CD274 is linked to cancer.